Duchenne muscular dystrophy
Conditions
Interventions
None listed
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: - Age between 4-15 years - Confirmation of the diagnosis of Duchenne Muscular Dystrophy by DNA mutation or muscle biopsy. - Who visit the DMD-out patient clinical of the LUMC for their annual visit
Exclusion criteria
Exclusion criteria: - Previous exposure to cardiac medication, including ACEi (history or current use) - Unable to lie in supine position for echocardiography - Impossibility to measure jugulum-symphysis distance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end-point of this study is the difference in PWV between DMD patients and published paediatric reference values. The primary end point of the follow up part of the study is the difference influence of ACEi treatment on arterial stiffness 3 months and 6 months after the start of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Relation between arterial stiffness and cardiac function at baseline and 12 months of the study Accuracy of PWV measured by Arteriograph versus PWV measured by cardiac MRI | — |
Contacts
Public ContactNienke van de Velde
Leiden University Medical Center
Outcome results
None listed